Why Your Phase II Application Needs Strong LOIs
Phase II reviewers at NSF, NIH, and DoD aren’t just evaluating your technology — they’re evaluating whether anyone will actually buy it. A well-structured Letter of Intent (LOI) from a potential customer or partner is one of the strongest signals of commercialization viability you can provide.
Most founders either skip LOIs entirely or submit vague “letters of support” that carry zero weight. This blueprint fixes that.
What Makes a Strong LOI
A compelling LOI has five critical elements:
- Specific problem acknowledgment — The signer explicitly states the pain point your technology addresses in their organization
- Intent to evaluate or pilot — Not a purchase commitment, but a clear willingness to test, pilot, or evaluate your solution
- Named decision-maker signature — VP-level or above, with title and organizational context
- Quantified impact potential — Even rough estimates of time/cost savings or capability gaps filled
- Timeline alignment — References to their procurement cycle or evaluation window
Key distinction: An LOI is not a purchase order. It’s a non-binding expression of intent to engage commercially. Reviewers know this — they’re looking for evidence that real conversations have happened with real buyers.
LOI Template Structure
Header Block
[Company Letterhead]
[Date]
To: [Program Officer Name / Review Panel]
Re: Letter of Intent — [Your Company Name] / [Solicitation Number]Body — Paragraph 1: Problem Context
“[Signer’s Organization] currently faces [specific operational challenge]. Our existing approach to [relevant process] results in [quantified inefficiency — hours, cost, error rate, etc.].”
Body — Paragraph 2: Technology Relevance
“We have reviewed [Your Company]‘s [technology/solution name] developed under SBIR Phase I Award [award number]. Based on our evaluation, this technology has the potential to [specific improvement] in our [department/workflow/mission area].”
Body — Paragraph 3: Intent to Engage
“Upon successful completion of Phase II development, [Signer’s Organization] intends to [evaluate / pilot / integrate] this solution within [specific department or use case]. We anticipate this evaluation could begin as early as [timeframe].”
Body — Paragraph 4: Commercialization Fit
“We believe the addressable market for this capability within [industry/sector] is significant. Organizations similar to ours face comparable challenges in [problem domain], and a validated solution could see broad adoption.”
Closing
Sincerely,
[Name]
[Title — VP level or above]
[Organization]
[Contact Information]Agency-Specific Formatting Notes
NSF (National Science Foundation)
- Emphasize broader impacts and market size
- Reference the specific SBIR/STTR solicitation topic
- NSF values LOIs from both commercial and government entities
NIH (National Institutes of Health)
- Focus on clinical utility and patient impact
- Include references to relevant disease areas or care settings
- Hospital system or health plan LOIs carry extra weight
DoD (Department of Defense)
- Emphasize mission relevance and operational readiness
- Reference specific program offices or acquisition pathways (PEOs, PMOs)
- Dual-use potential (military + commercial) strengthens the narrative
Common Mistakes That Weaken LOIs
| Mistake | Why It Hurts | Fix |
|---|---|---|
| Generic “letter of support” language | Reads as a favor, not genuine commercial interest | Use specific problem/solution language |
| Signed by junior staff | Signals lack of organizational commitment | Get VP+ or department head signatures |
| No quantified impact | Reviewers can’t assess commercial potential | Include even rough $ or time estimates |
| Copy-pasted across applications | Reviewers notice — it signals low effort | Customize each LOI per signer |
| Missing company letterhead | Looks unofficial | Always use official letterhead |
How Many LOIs Do You Need?
- NSF: 2–3 strong LOIs is competitive; 5+ is exceptional
- NIH: 1–2 from clinical end-users + 1 from industry partner is ideal
- DoD: 1 from a relevant program office + 1–2 from primes or end-users
Pro tip: Start LOI conversations during Phase I. Don’t wait until the Phase II proposal deadline. The best LOIs come from organizations you’ve already done discovery calls with.
Getting the LOI Signed
The hardest part isn’t writing the template — it’s getting a busy VP to actually sign it. Here’s the approach that works:
- Do the work for them. Draft the LOI yourself based on your discovery conversations. Send it ready to sign.
- Make it easy to modify. Send as a Word doc, not a PDF. Let them adjust language to fit their compliance requirements.
- Give them a deadline. “We’re submitting our Phase II proposal on [date]. Could we have this returned by [date - 2 weeks]?”
- Follow up exactly once. If they don’t respond, they’re not a real prospect. Move on.
This blueprint is part of the Phase II Commercialization Vault — free resources for SBIR/STTR founders navigating the path from Phase I to commercial traction.